Bionet

Bionet, founded in 1999, is Taiwan's first private cord blood bank and the only publicly listed company in the stem cell industry. It possesses exceptional innovation and technology development capabilities. Since its establishment, Bionet has been dedicated to integrating two major technological industries: stem cells and genetics. The company has pioneered numerous new products and services, including stem cell storage for cord blood, cord tissue, teeth, and various genetic and testing-related services, positioning itself as a trailblazer in the Asian stem cell industry. Bionet upholds the corporate spirit of "using biotech power to create better quality of life" and, with its most comprehensive product services and storage quality, has become Asia's largest and the world's third-largest stem cell database. The company has supplied hundreds of stem cell samples for transplants worldwide, establishing itself as a key international stem cell supplier, expanding the cycle of goodwill across the globe. In 2012, Bionet’s subsidiary, Chuangyuan Biotech (4160), successfully went public, becoming the only company listed in both the genetics and bioinformatics sectors. By integrating gene technology, information technology, and healthcare, Bionet Group serves over 50% of newborns in Taiwan, successfully establishing a new cross-sector operational model, once again setting a unique industry milestone!

Bionet Corporation

Industry

What We Did

Brand Video

Description

Bionet, established in 1999, has become one of Asia's most internationally recognized biotech brands, with three core capabilities: "Regenerative Medicine/Cell Therapy," "Precision Health/Genomic Medicine," and "Molecular Digital Technology/Smart R&D." Under its umbrella, "Bionet Biotech" (Taiwan's first publicly listed company focused on cell therapy, established in 2007) and "Bionet Gene" (formerly known as Chuangyuan Biotech, Taiwan's first publicly listed company focused on genomic medicine and scientific information, established in 2012) have served over 51% of newborns in Taiwan, 90% of obstetrics and gynecology hospitals, and reproductive medicine centers, expanding to 17 countries overseas, with a total customer base of 1.5 million.

Bionet has been approved by Taiwan's Ministry of Health and Welfare for specialized cell therapies, including adipose-derived stem cells for degenerative arthritis, knee cartilage defects, and chronic wounds, as well as immune cell CIK therapy for colorectal cancer, lung cancer, breast cancer, liver cancer, and more. The company continues to expand its regenerative medicine and cell therapy applications, improve aesthetic products/hair growth development, and advance quality and technology in next-generation exosomes (Meta-Exosome) and cell-derived products and processes. In 2022, Bionet established "Bionet Cell Therapeutics Co., Ltd." to accelerate the development of regenerative medical cell formulations, exosome diagnostics, and treatments, combining smart R&D, excellent gene and cell therapy development technologies, and digital simulation innovations to provide broader services.

Project Challenge
Bionet wanted to clearly showcase its professionalism in the biotech field through a video, emphasizing its advanced technologies and service value. Additionally, the video needed to highlight the company's professionalism in the research process and communicate its core technologies and services with an international perspective.

Strategy and Creativity
To effectively communicate Bionet's brand value, GeBo Brand Marketing Consultants produced a corporate image video. Using carefully designed computer animations, the video vividly demonstrated Bionet's expertise in the research and development process. The video, with an English voiceover, clearly explained the company's core technologies and services, emphasizing its leadership in regenerative medicine, precision health, and molecular digital technology. This combination of visuals and language successfully conveyed Bionet's professional image and technological strength to the audience.

Related cases

Our Newsletter

Subscribe

genuinely useful brand and marketing perspectives.

Send us a Message

Contact Form - EN